The May 24, 2022, session of Duke Medicine LEADS featured Daniel Parker, MD presenting on "Advances in Alzheimer's Disease: Prevention, Diagnosis, and Treatment."
Treating hypertension and hearing loss may reduce the incidence of ADRD.
Blood-based biomarkers for the diagnosis of AD in patients with cognitive decline are becoming available for clinical use.
There is currently insufficient evidence to recommend anti-amyloid therapy for treatment of cognitive decline due to AD.
Duke Medicine Learning, Education, and Discussion Series (LEADS) takes place each Tuesday at 12 p.m. Learn more and see schedule of upcoming sessions.